Citigroup’s Kairos Pharma KAPA Stock Holding History

Citigroup’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$6	–	6352
2026 Q1	$6	Buy	+1	New	+$5	﹤0.01%	5770
2025 Q3	–	Sell	-786	Closed	-$3.9K	–	6370
2025 Q2	$3.9K	Buy	+786	New	+$4K	﹤0.01%	5305

Other funds holding KAPA

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SFG

SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citigroup's KAPA Position: Q2 2026 in Review

Citigroup sold out of Kairos Pharma (KAPA) in Q2 2026, closing a stake of 1 share — an estimated $6 sold.

Citigroup first reported a position in KAPA in Q2 2025 and held it in 2 quarters. The position peaked at $3.9K in Q2 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

Citigroup reported no remaining Kairos Pharma position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 Kairos Pharma share in Q2 2026, an estimated $6.
Citigroup first reported a position in Kairos Pharma in Q2 2025 and held it in 2 quarters.
Citigroup's Kairos Pharma position peaked at $3.9K in Q2 2025.
14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.